Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of enzomenib in relapsed or refractory acute leukemia with KMT2A rearrangement or NPM1 mutation
2022-502741-10-00Phase 2Authorised
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of enzomenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage (ALAL) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-limiting toxicities, CR + CRh and 4 more. Planned start Jan 2024; status: authorised.
02
Drugs
enzomenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on 2022-502741-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502741-10-00.